TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28566400

Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty and supervised exercise treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Supervised exercise treatment alone
Number of subjects: 140
Study: 26400874

Group type: EXPERIMENTAL
Intervention: Morning dosing of antihypertensive medications
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Nighttime dosing of antihypertensive medications
Number of subjects: 17000
Study: 23755867

Group type: EXPERIMENTAL
Intervention: Ivabradine 2.5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 21364485

Group type: EXPERIMENTAL
Intervention: Constant-Torque (CT) stretching
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Constant-Angle (CA) stretching
Number of subjects: 17
Study: 19138567

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (thioridazine, chlorpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (thioridazine, chlorpromazine, haloperazine, trifluoperazine, or risperidone) for 12 months
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (thioridazine, chlorpromazine, haloperidone, trifluoperazine, or risperidone) for 12 months
Number of subjects: 165
Study: 18236771

Group type: EXPERIMENTAL
Intervention: Tailored interventions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tailored behavioral interventions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tailored psychosocial and biological interventions
Number of subjects: 63
Study: 14756608

Group type: EXPERIMENTAL
Intervention: Telephone-delivered, coping improvement group intervention
Number of subjects: 329
Study: 11224633

Group type: EXPERIMENTAL
Intervention: Choledochocholedochostomy with T tube
Number of subjects: 180

Group type: COMPARATOR
Intervention: Choledochocholedochostomy without T tube
Number of subjects: 180
Study: 10096047

Group type: EXPERIMENTAL
Intervention: Fresh urine samples examined within 4 hours
Number of subjects: 40
Study: 7819171

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of Latanoprost and Timolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of Timolol and Latanoprost
Number of subjects: 19
Study: 3337191

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha 1-isopropylester, 1.120 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polysorbate 80 in saline (control)
Number of subjects: 20
Study: 31841417

Group type: EXPERIMENTAL
Intervention: Error Augmentation (EA) in immersive VR
Number of subjects: 17

Group type: COMPARATOR
Intervention: Training without Error Augmentation (EA)
Number of subjects: 17
Study: 29770146

Group type: EXPERIMENTAL
Intervention: Real 20 Hz rTMS applied to the left primary motor cortex for 5 consecutive days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham 20 Hz rTMS
Number of subjects: 6
Study: 27387193

Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Diagnostic Scale (PDS) and Center for Epidemiologic Studies‐Depression Scale (CES‐D)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Brief Symptom Inventory (BSI) and CES‐D
Number of subjects: 104
Study: 25398701

Group type: EXPERIMENTAL
Intervention: Anti-arrhythmic medication
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Non-selective beta-blocker
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Statin
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Other cardiovascular and psychotropic medication
Number of subjects: 2407
Study: 23769289

Group type: EXPERIMENTAL
Intervention: Body Psychotherapy (BPT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 31
Study: 21432752

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 40
Study: 18694635

Group type: EXPERIMENTAL
Intervention: 3 x 300 mg/day WS 5570
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study: 16823303

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Number of subjects: 82

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 82
Study: 12707127

Group type: EXPERIMENTAL
Intervention: IV lidocaine 2 mg/kg
Number of subjects: 0
Study: 10624972

Group type: EXPERIMENTAL
Intervention: F(IO)2 of 0.4 during one-lung ventilation (OLV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: F(IO)2 of 0.6 during OLV
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: F(IO)2 of 1.0 during OLV
Number of subjects: 24

Group type: COMPARATOR
Intervention: Two-lung ventilation (TLV)
Number of subjects: 24
Study: 15321262

Group type: EXPERIMENTAL
Intervention: sufentanil 7.5 microg (1.5 ml)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: sufentanil 5 microg + bupivacaine 1 mg (1.5 ml)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: bupivacaine 1.75 mg, sufentanil 1.05 microg and epinephrine 1.75 microg (1.5 ml)
Number of subjects: 25
Study: 1585754

Group type: EXPERIMENTAL
Intervention: UVAB (combined UVA-UVB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UVB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UVAB
Number of subjects: 0
Study: 3897614

Group type: EXPERIMENTAL
Intervention: 2:8 form
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 4:6 form
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 6:4 form
Number of subjects: 364

Group type: COMPARATOR
Intervention: CCL form
Number of subjects: 364
Study: 30636281

Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg (Neurontin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg (Gabasandoz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional batch of Gabapentin
Number of subjects: 0
Study: 29049611

Group type: EXPERIMENTAL
Intervention: Prophylactic up‐front surgery within 6 months from diagnosis combined with oncologic treatment
Number of subjects: 363

Group type: COMPARATOR
Intervention: Nonsurgical treatment or delayed surgery as needed combined with oncologic treatment
Number of subjects: 363
Study: 26077904

Group type: EXPERIMENTAL
Intervention: 14-week behavioral intervention using video instructional materials, workbook and telephone coaching in behavioral management, pleasant events scheduling, and relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic education guide and telephone support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14-week behavioral intervention
Number of subjects: 0
Study: 24359036

Group type: EXPERIMENTAL
Intervention: PIPAC intervention (four-session, multi-component intervention focused on reminiscence and future planning)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Minimal support phone contact (comparison group)
Number of subjects: 19
Study: 22253270

Group type: EXPERIMENTAL
Intervention: Remimazolam (0.01-0.3 mg/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Remimazolam (6 mg initial loading dose followed by 3 mg maintenance doses)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 54
Study: 20375406

Group type: EXPERIMENTAL
Intervention: T12PR24 (telaprevir for 12 weeks + peginterferon alfa-2a and ribavirin for 24 weeks)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: T24PR48 (telaprevir for 24 weeks + peginterferon alfa-2a and ribavirin for 48 weeks)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: T24P24 (telaprevir and peginterferon alfa-2a for 24 weeks)
Number of subjects: 453

Group type: COMPARATOR
Intervention: PR48 (control group, peginterferon alfa-2a and ribavirin for 48 weeks)
Number of subjects: 453
Study: 17377863

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel + hemoclips (Group II)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Electrocautery + hemoclips (Group I)
Number of subjects: 200
Study: 15728298

Group type: EXPERIMENTAL
Intervention: CoQ10 (3 x 100 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 11949645

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline
Number of subjects: 40
Study: 9807845

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tramadol HCl 1.5 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tenoxicam 0.3 mg/kg
Number of subjects: 120
Study: 7665860

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (Cefotaxime + Metronidazole)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 61
Study: 2526271

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (31/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 14
Study: 27008619

Group type: EXPERIMENTAL
Intervention: Counterconditioning group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Extinction group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 28035736

Group type: EXPERIMENTAL
Intervention: Whole-grain rye porridges (40 g)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Whole-grain rye porridges (55 g)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rye porridge enriched with inulin: gluten proportions (9:3 g)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rye porridge enriched with inulin: gluten proportions (6:6 g)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rye porridge enriched with inulin: gluten proportions (3:9 g)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Refined wheat bread (control, 55 g)
Number of subjects: 21
Study: 25660206

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion to sleep deeper before a midday nap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control tape before a midday nap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion
Number of subjects: 0
Study: 23257734

Group type: EXPERIMENTAL
Intervention: Mosapride citrate 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study: 21091527

Group type: EXPERIMENTAL
Intervention: Air-abrasive device (AM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (LM)
Number of subjects: 42
Study: 18805963

Group type: EXPERIMENTAL
Intervention: Recombinant asparaginase preparation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Asparaginase medac
Number of subjects: 32
Study: 16407508

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg per day (group 1)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg per day (group 2)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Benazepril and Placebo (group 2)
Number of subjects: 422
Study: 14585010

Group type: EXPERIMENTAL
Intervention: Simultaneous performance of pronouncing 'A' or 'B' and making a manual left or right response to arrows.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative control procedure mixing manual and vocal tasks.
Number of subjects: 0
Study: 11320566

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 74

Group type: COMPARATOR
Intervention: Observation without treatment
Number of subjects: 74
Study: 8795669

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (UNDW)
Number of subjects: 17
Study: 1505913

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13 to 15 mg/kg body wt/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 14
Study: 6440383

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 44
Study: 30523504

Group type: EXPERIMENTAL
Intervention: UV skin damage visuals
Number of subjects: 2219

Group type: COMPARATOR
Intervention: Mole removal visuals
Number of subjects: 2219

Group type: COMPARATOR
Intervention: Other visual conditions
Number of subjects: 2219

Group type: COMPARATOR
Intervention: Visual efficacy conditions
Number of subjects: 2219
Study: 30223451

Group type: EXPERIMENTAL
Intervention: Plant-based high-carbohydrate, low-fat (vegan) diet (n = 38)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Current diet (n = 37)
Number of subjects: 75
Study: 27157029

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined participants (N = 26)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 28
Study: 24804364

Group type: EXPERIMENTAL
Intervention: Educational intervention for patients only
Number of subjects: 823

Group type: COMPARATOR
Intervention: No education
Number of subjects: 823
Study: 22435936

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Conservative treatment group
Number of subjects: 1173
Study: 19307037

Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isocaloric standard fibre‐containing formula (SF)
Number of subjects: 12
Study: 16306064

Group type: EXPERIMENTAL
Intervention: Certified facilities (intervention group)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-certified facilities (control group)
Number of subjects: 170
Study: 14583133

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 3179
Study: 10762503

Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Vascular dementia (VaD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Clinical scale assessment
Number of subjects: 155
Study: 9041090

Group type: EXPERIMENTAL
Intervention: Amvisc
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Amvisc Plus
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 69
Study: 1375684

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no inotropic therapy)
Number of subjects: 48
Study: 3965373

Group type: EXPERIMENTAL
Intervention: Retinyl acetate (RA) gel 3 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Retinyl acetate (RA) gel 6 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Retinyl acetate (RA) gel 9 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Retinyl acetate (RA) gel 18 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30674038

Group type: EXPERIMENTAL
Intervention: BC 007 (ssDNA therapeutic)
Number of subjects: 0
Study: 29575006

Group type: EXPERIMENTAL
Intervention: Molidustat 50 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Molidustat (doses of 12.5 mg and above)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All doses of molidustat
Number of subjects: 59
Study: 26442829

Group type: EXPERIMENTAL
Intervention: TAC level(t) <4.0 ng/ml
Number of subjects: 528

Group type: COMPARATOR
Intervention: TAC level(t) ≥4.0 ng/ml
Number of subjects: 528
Study: 24580383

Group type: EXPERIMENTAL
Intervention: Epidural 0.75% levobupivacaine 12 ml with 1 ml (0.5 µg/kg) of dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural 0.75% levobupivacaine 12 ml with 1 ml of isotonic sodium chloride solution
Number of subjects: 40
Study: 22114200

Group type: EXPERIMENTAL
Intervention: Berg Balance Scale (BBS)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Performance‐Oriented Mobility Assessment total scale (POMA‐T)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: POMA balance subscale (POMA‐B)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dynamic Gait Index (DGI)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Lower baseline balance subgroup
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Total sample
Number of subjects: 111
Study: 20816902

Group type: EXPERIMENTAL
Intervention: MVA.HIVA vaccination
Number of subjects: 0
Study: 17701000

Group type: EXPERIMENTAL
Intervention: Partial thinning
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Circumferential thinning
Number of subjects: 163

Group type: COMPARATOR
Intervention: Zona intact
Number of subjects: 163
Study: 16697169

Group type: EXPERIMENTAL
Intervention: Lipidic matricial form (M)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lipidic physical blend formulation (PB)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler (control)
Number of subjects: 6
Study: 12800415

Group type: EXPERIMENTAL
Intervention: Manshuailing Oral Liquid (MSL) 100 ml, 2 times a day for 4 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional treatment with western drugs (cardiotonic, diuretic, coronary dilator, etc.)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Manshuailing Oral Liquid (MSL) in patients with mixed heart failure (systolic and diastolic dysfunction)
Number of subjects: 90
Study: 11193499

Group type: EXPERIMENTAL
Intervention: Intertrochanteric hip fracture treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (50 patients, mean age 62.4 years)
Number of subjects: 60
Study: 9004441

Group type: COMPARATOR
Intervention: 0 mg GMDP
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 5 mg GMDP
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 25 mg GMDP
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 50 mg GMDP
Number of subjects: 153
Study: 1279948

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound scan
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mathematical formula for estimating weight
Number of subjects: 41
Study: 3976733

Group type: EXPERIMENTAL
Intervention: Teacher personality construct (abstract vs. concrete conceptual system)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Pupil variables (race, school behavior)
Number of subjects: 454
Study: 29420997

Group type: EXPERIMENTAL
Intervention: l-carnosine 500 mg (2 capsules)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 27959941

Group type: EXPERIMENTAL
Intervention: Oral medication
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravenous infusion
Number of subjects: 59
Study: 25205644

Group type: EXPERIMENTAL
Intervention: Endovascular procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 0
Study: 23063851

Group type: EXPERIMENTAL
Intervention: Mother-Infant Transaction Program (n = 61)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (n = 57)
Number of subjects: 118
Study: 20660002

Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 308

Group type: COMPARATOR
Intervention: Antithyroid drugs (medical treatment)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Patients with TAO (regardless of treatment)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Patients without TAO
Number of subjects: 308
Study: 18822620

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg daily subcutaneously
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no teriparatide)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 82
Study: 16019582

Group type: EXPERIMENTAL
Intervention: Sahaja Yoga meditation (SYM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 12200983

Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/day) for 28 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 63
Study: 10613070

Group type: EXPERIMENTAL
Intervention: Visible time-counter during CPAP accommodation
Number of subjects: 20

Group type: COMPARATOR
Intervention: No visible time-counter during CPAP accommodation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subjective estimation of time with no visible counter
Number of subjects: 20
Study: 7560219

Group type: EXPERIMENTAL
Intervention: Triclosan applied after histamine reaction
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Triclosan pre-treatment before histamine application
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Other phenols tested
Number of subjects: 9
Study: 1951545

Group type: EXPERIMENTAL
Intervention: Clindamycin (3 days intravenously and 4 days orally)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 7012995

Group type: EXPERIMENTAL
Intervention: Bacampicillin (800 mg twice daily for 14 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ampicillin (500 mg four times daily for 14 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bacampicillin and Ampicillin
Number of subjects: 16
Study: 31522159

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) at a dose of 70 mg once weekly for six months plus local debridement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lepidium sativum (LS; 1 gm tid for six weeks) plus local debridement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined treatment of LS (1 gm tid for six weeks) and ALN (70 mg once weekly for six months) plus local debridement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (local debridement only)
Number of subjects: 45
Study: 28287324

Group type: EXPERIMENTAL
Intervention: Home delivery meal service providing energy‐dense, protein‐rich meals delivered 3 times per week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group continued their habitual diet
Number of subjects: 40